BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer

The significant activity of poly(ADP-ribose)polymerase (PARP) inhibitors in the treatment of germline BRCA mutation-associated ovarian cancer, which represents ∼15% of HGS cases, has recently led to European Medicines Agency and food and drug administration approval of olaparib. Accumulating evidenc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2016-08, Vol.27 (8), p.1449-1455
Hauptverfasser:	Moschetta, M., George, A., Kaye, S.B., Banerjee, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	BRCA BRCA1 Protein - genetics BRCA2 Protein - genetics Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - genetics Cystadenocarcinoma, Serous - pathology DNA Methylation - drug effects Female Germ-Line Mutation - genetics Homologous Recombination - drug effects Humans methylation ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use somatic mutation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!